Express Scripts Holding Co.'s decision to actively encourage providers to prescribe a compounded alternative to the commercially available product Daraprim marks a new direction in payers' push against rapid price increases for off-patent drugs.
The pharmacy benefit manager announced its decision Dec. 1, saying it has partnered with Imprimis Pharmaceuticals Inc. to compound...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?